Masimo Corp
NASDAQ:MASI

Watchlist Manager
Masimo Corp Logo
Masimo Corp
NASDAQ:MASI
Watchlist
Price: 137.4 USD -0.68% Market Closed
Market Cap: 7.4B USD

Masimo Corp
Investor Relations

Masimo Corp., a pioneering force in noninvasive monitoring technologies, was founded in 1989 by Joe Kiani, who envisioned a healthcare landscape imbued with precision and accessibility. The company rose to prominence with its innovative pulse oximetry technology, a tool crucial for measuring oxygen levels in patients' blood. Unlike traditional methods, Masimo's technology utilizes proprietary signal extraction techniques that allow it to deliver accurate readings even in challenging conditions such as movement or low perfusion. This innovation not only revolutionized patient monitoring but also secured Masimo significant market share within hospitals and healthcare facilities worldwide. Their devices, known for their reliability, feed into a recurring revenue model, as hospitals and medical professionals constantly require new sensors and related consumables to operate the equipment effectively.

In addition to pulse oximetry, Masimo has skillfully expanded its portfolio to encompass advanced monitoring systems such as those measuring brain function and hydration levels, offering a comprehensive suite of solutions for enhanced patient care. They have ventured into consumer health as well, with devices that allow people to monitor their health metrics at home. This broadening of scope positions Masimo as a versatile player across both professional and consumer markets. By continually investing in research and development, Masimo aims to address unmet clinical needs and open new revenue streams, thus sustaining its growth trajectory in the competitive landscape of medical technology. Through strategic partnerships and acquisitions, the company has consistently augmented its capabilities, solidifying a robust financial performance anchored in its commitment to innovation and quality.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 4, 2025
AI Summary
Q3 2025

Revenue Growth: Masimo delivered 8% revenue growth in Q3, with healthcare revenue reaching $371 million.

EPS & Margins: EPS rose 38% year-over-year to $1.32, and operating margin improved to 27.1%, up 450 basis points.

Guidance Update: Full-year revenue guidance was tightened to $1.51–$1.53 billion, while operating margin and EPS guidance were both raised.

Strong Demand: The company reported robust demand, highlighted by record incremental contract value of $124 million and 8% more technology boards shipped.

Capital Allocation: Masimo returned $350 million to shareholders via stock repurchases and used proceeds from a divestiture to pay down debt.

AI & Innovation: Continued investment in intelligent monitoring, wearables, and AI-enabled sensors, with key product launches and studies underway.

Commercial Execution: Ongoing realignment of sales force and enhancements in advanced monitoring are beginning to show positive results.

Key Financials
Revenue
$371 million
EPS
$1.32
Operating Cash Flow
$57 million
Gross Margin
62.2%
Operating Margin
27.1%
Incremental Contract Value
$124 million
Unrecognized Contract Revenue (next 12 months)
$507 million
Technology Boards and Modules Shipped
66,000
Capital Returned to Shareholders
$350 million
Share Repurchases
2.4 million shares
Earnings Call Recording
Other Earnings Calls

Management

Ms. Michelle M. Brennan
Interim CEO & Director
No Bio Available
Mr. Micah Young CPA
Executive VP & CFO
No Bio Available
Mr. Bilal Muhsin
Chief Operating Officer
No Bio Available
Mr. Thomas Samuel McClenahan J.D.
Executive VP, General Counsel & Corporate Secretary
No Bio Available

Contacts

Address
CALIFORNIA
Irvine
52 Discovery
Contacts
+19492977000.0
www.masimo.com